Abstract

BackgroundThe individual and societal burden of hand eczema is high. Literature indicates that moderate to severe hand eczema is a disease with a poor prognosis. Many patients are hampered in their daily activities, including work. High costs are related to high medical consumption, productivity loss and sick leave. Usual care is suboptimal, due to a lack of optimal instruction and coordination of care, and communication with the general practitioner/occupational physician and people involved at the workplace. Therefore, an integrated, multidisciplinary intervention involving a dermatologist, a care manager, a specialized nurse and a clinical occupational physician was developed. This paper describes the design of a study to investigate the effectiveness and cost-effectiveness of integrated care for hand eczema by a multidisciplinary team, coordinated by a care manager, consisting of instruction on avoiding relevant contact factors, both in the occupational and in the private environment, optimal skin care and treatment, compared to usual, dermatologist-led care.MethodsThe study is a multicentre, randomized, controlled trial with an economic evaluation alongside. The study population consists of patients with chronic, moderate to severe hand eczema, who visit an outpatient clinic of one of the participating 5 (three university and two general) hospitals. Integrated, multidisciplinary care, coordinated by a care manager, including allergo-dermatological evaluation by a dermatologist, occupational intervention by a clinical occupational physician, and counselling by a specialized nurse on optimizing topical treatment and skin care will be compared with usual care by a dermatologist. The primary outcome measure is the cumulative difference in reduction of the clinical severity score HECSI between the groups. Secondary outcome measures are the patient's global assessment, specific quality of life with regard to the hands, generic quality of life, sick leave and patient satisfaction. An economic evaluation will be conducted alongside the RCT. Direct and indirect costs will be measured. Outcome measures will be assessed at baseline and after 4, 12, 26 and 52 weeks. All statistical analyses will be performed on the intention-to-treat principle. In addition, per protocol analyses will be carried out.DiscussionTo improve societal participation of patients with moderate to severe hand eczema, an integrated care intervention was developed involving both person-related and environmental factors. Such integrated care is expected to improve the patients' clinical signs, quality of life and to reduce sick leave and medical costs. Results will become available in 2011.

Highlights

  • The individual and societal burden of hand eczema is high

  • In this paper, we describe the design of a randomized controlled trial (RCT) comparing integrated care for hand eczema by a multidisciplinary team, with usual care by a dermatologist

  • Usual care mainly focuses on improving clinical signs of hand eczema and does not have major focus on the patient's participation in society

Read more

Summary

Methods

Design of the study The design of the study is a randomized controlled trial with a full economic evaluation alongside, with a followup of one year. The patients' own general practitioner, occupational physician and treating medical specialist will be informed by letter about the study and the allocation of their patient to the usual care group They will be asked to adhere to their normal treatment for hand eczema. The cost calendar includes direct costs relevant to the treatment of hand eczema, such as visits to the general practitioner, occupational physician or occupational hygienist and purchase of medication. The patient's general practitioner will receive a letter, in which he/she is asked to leave the treatment of hand eczema to the multidisciplinary staff. The cost calendars will include direct health care costs relevant to the treatment of hand eczema, such as visits to a general practitioner or an occupational practitioner and selfbought medication or skin protection tools. To compare the results of the cost-effectiveness analysis with other conditions, general health status will be measured according to the Dutch version of the EuroQol EQ-5D [18]

Discussion
Background
Objective
Koch P
Findings
18. Dolan P
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call